Business
Parsortix in RNA analysis of CTCs as tool in NSCLC
Parsortix in RNA analysis of CTCs as tool in NSCLC.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1060U\n Angle PLC\n 01 December 2021\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 1 December 2021\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n ANGLE'S PARSORTIX SYSTEM KEY TO STUDY DEMONSTRATING RNA ANALYSIS OF CTCs AS A PROGNOSTIC TOOL IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS \n \n \n \n \n \n Research published by world-class cancer research centre highlights critical advantages of the Parsortix system\n \n \n \n \n \n Multi-marker transcriptomic analysis (RNA) of CTCs reveals multiple subtypes with different prognostic significance\n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, \n is pleased to announce the publication of new clinical research undertaken by the world-class team at the Medical University of Vienna, Austria. The study in Non-Small Cell Lung Cancer (NSCLC) patients utilised ANGLE's Parsortix® system to isolate circulating tumour cells (CTCs) for enumeration and gene expression analysis (RNA). The Parsortix system was selected by researchers for the study due to its ability to provide unbiased CTC enrichment enabling the isolation of non-epithelial cancer cells together with exceptional depletion of white blood cells, which is key for molecular analysis. \n \n \n \n \n \n In preliminary spiking experiments, CTC capture rates for the Parsortix system were established with two NSCLC cell lines spiked into healthy volunteer blood. Capture rates as high as 80% were observed, further confirming the high capture rates observed in previous studies. Blood was then collected either at baseline or at disease progression in 118 NSCLC patients and processed with the Parsortix system. The cells harvested by the Parsortix system were subjected to RNA molecular analysis using standard downstream analysis techniques to generate gene expression information. \n \n \n \n \n \n The researchers report that in patients where a subset of CTCs had cancer stem cell (CSC) properties, significantly worse patient outcomes both at diagnosis and at disease progression were observed. CSCs are non-epithelial CTCs with a high degree of cell plasticity and heterogeneity making them highly adaptable and resistant to treatment and potentially representing a new avenue for drug discove...